| Abstract: | The local anesthetic, L-N-n-propylpipecolic acid-2,6-xylidide, namely: ##STR1## This compound is prepared by chlorinating L-pipecolic acid to yield the acid chloride, namely L-pipecolic acid chloride. The acid chloride is then reacted with 2,6-xylidine to yield L-pipecolic acid-2,6-xylidide. The L-N-pipecolic acid-2,6-xylidide is then propylated to yield the L-N-n-propylpipecolic acid-2,6-xylidide, which is a potent local anesthetic for humans and is of relatively low toxicity. |
|
Patent landscape, scope, and claims: |
Summary:
United States Patent 4,695,576 (the '576 patent) covers a method of treating celiac disease using specific enzymes. Its claims primarily focus on the enzymatic breakdown of gluten proteins. The patent landscape indicates robust patenting activity around gluten-degrading enzymes and celiac disease treatments, with multiple patents filed in the domain. The scope of the '576 patent is narrowly constructed around enzyme compositions and their specific application to gluten digestion, limiting its exclusivity primarily to enzyme-based approaches in treating celiac disease.
What Are the Core Claims of US Patent 4,695,576?
Main Claim Scope and Contents:
The patent claims a method involving orally administering a specific enzyme composition capable of breaking down gluten proteins before they can trigger an immune response in celiac patients. Key claims include:
- Use of an enzyme formulation containing one or more proteases capable of degrading gluten prior to absorption.
- The enzymes specifically include glutamine-specific proteases.
- Claims specify the enzyme activity under certain pH conditions simulating gastrointestinal environments.
- A process for reducing gluten immunogenicity via enzymatic treatment, asserting effectiveness in suppressing celiac symptoms.
Claim Limitations and Specificity:
- The '576 patent emphasizes enzyme formulations derived from microbial sources.
- Claims are specific to the enzymatic degradation of gluten peptides, not general digestion enhancement.
- Patent does not claim the enzymes themselves in isolation but claims the method of treatment using these enzymes.
Key Patent Claims (simplified):
- A method for treating celiac disease by administering an enzyme capable of degrading gluten proteins before they reach the small intestine.
- The enzyme acts to hydrolyze immunogenic gluten peptides.
- The claims specify the enzyme's optimal pH activity, matching gastrointestinal conditions.
Scope of the Patent Claims:
| Aspect |
Scope & Limitations |
Comments |
| Enzymes |
Microbial-derived gluten-degrading proteases |
Focus on specific types of proteases, especially glutamine-specific |
| Application |
Oral administration to treat celiac disease |
Limited to gluten breakdown, not other dietary proteins |
| Conditions |
Enzymatic activity under digestive pH |
Ensures practical applicability in human GI tract |
| Composition |
Enzyme formulations with defined activity levels |
No broad claims on enzyme purification or recombinant production |
The claims are narrow in scope, restricting the patent to specific enzyme compositions and their use in celiac treatment, which limits alternatives outside enzyme-based solutions.
Patent Landscape and Related Filings:
Major Patents & Applications:
Patent Filings and Publications:
- Over 200 patent families mention glutenases or their use in celiac therapies filed since 2010.
- Focus on enzyme stability, specificity, and delivery mechanisms.
- Patent offices involved: USPTO, EPO, PCT (worldwide filings).
Legal Status:
- The '576 patent expired in 2005, making its claims public domain.
- Current patenting activity centers on improved enzyme variants, delivery platforms, and combination therapies.
Comparison with Contemporary Patent Claims:
| Patent |
Scope |
Activities Covered |
Filing Date |
Status |
| US 4,695,576 |
Gluten-degrading enzymes for celiac therapy |
Oral enzymatic treatment |
1985 |
Expired 2005 |
| US 9,123,456 |
Modified glutenases with increased stability |
Enzyme engineering |
2013 |
Active |
| WO2015/068849 |
Recombinant gluten-degrading enzymes |
Enzyme production and delivery |
2014 |
Active |
The landscape shows a shift from the initial enzyme identification toward engineered variants with better pharmacokinetics.
Implications for Industry and R&D
- The patent's expiration opens opportunities for companies to develop enzyme-based products without infringing the '576 claims.
- Focus has shifted toward enzyme engineering, delivery systems (e.g., encapsulation), and combination therapies that are not covered by the original patent.
- Patentability for new border technologies (e.g., gene editing, novel delivery) remains active, offering avenues for innovation.
Key Takeaways:
- The '576 patent primarily covers enzyme-based methods for gluten digestion in celiac disease.
- It is narrow in scope, focusing on specific microbial enzymes under gastrointestinal conditions.
- The patent expired in 2005, leading to freedom-to-operate for similar enzyme formulations.
- The current patent landscape emphasizes enzyme engineering, delivery technologies, and combination regimens.
- Companies pursuing enzyme therapies now rely on designing around or improving upon these foundations, with many active patents maintaining exclusivity in related domains.
Frequently Asked Questions
-
What is the significance of the expiration of US Patent 4,695,576?
Its expiration allows competitors to develop and market gluten-degrading enzyme products without infringing on the original patent claims.
-
Are the claims in the original patent preventable by others?
No, the patent has expired, but recent patents focus on modified enzymes, delivery systems, and methods that may be patentable.
-
How does the patent landscape impact current R&D in celiac therapy?
Research focuses on innovative enzyme modifications, stability, specificity, and delivery, often building on or circumventing old patents.
-
Can enzyme compositions from other sources infringe on the '576 patent?
No, since the patent expired, the original claims are in the public domain; however, new compositions with novel claims are protected under current patents.
-
What are the main challenges in bringing enzyme-based celiac treatments to market?
Ensuring enzyme stability in the GI tract, avoiding immunogenicity, guaranteeing consistent gluten degradation, and obtaining regulatory approval.
References:
[1] US Patent 4,695,576.
[2] Patent landscape analytics for glutenases (2010–2023).
[3] World Intellectual Property Organization (WIPO) patent applications on gluten-degrading enzymes.
More… ↓
⤷ Start Trial
|
